- Home
- FHN vs EXAS Comparison
FHN vs EXAS Comparison
Compare FHN & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FHN | EXAS |
|---|---|---|
| Founded | 1864 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 11.0B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FHN | EXAS |
|---|---|---|
| Price | $22.86 | $101.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 20 |
| Target Price | $24.05 | ★ $76.38 |
| AVG Volume (30 Days) | 5.7M | ★ 10.3M |
| Earning Date | 01-15-2026 | 11-03-2025 |
| Dividend Yield | ★ 2.64% | N/A |
| EPS Growth | ★ 20.88 | N/A |
| EPS | ★ 1.65 | N/A |
| Revenue | ★ $3,184,000,000.00 | $3,082,033,000.00 |
| Revenue This Year | $12.70 | $19.40 |
| Revenue Next Year | $2.54 | $13.51 |
| P/E Ratio | $13.75 | ★ N/A |
| Revenue Growth | 3.68 | ★ 14.47 |
| 52 Week Low | $15.19 | $38.81 |
| 52 Week High | $23.70 | $101.87 |
Technical Indicators
Market Signals| Indicator | FHN | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 62.34 | 89.74 |
| Support Level | $22.26 | $100.98 |
| Resistance Level | $22.98 | $101.43 |
| Average True Range (ATR) | 0.50 | 2.25 |
| MACD | 0.15 | 0.53 |
| Stochastic Oscillator | 91.86 | 97.74 |
Price Performance
Historical ComparisonAbout FHN First Horizon Corporation
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The company's reportable segments are: Commercial, Consumer & Wealth, Wholesale, and Corporate. The majority of its revenue is generated from Commercial, Consumer & Wealth. The Commercial, Consumer & Wealth segment offers financial products and services, including traditional lending and deposit taking, to commercial and consumer clients in the southern USA and other selected markets.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.